TesoRx is a clinical-stage biopharmaceutical company that has developed an innovative oral drug delivery platform aimed at addressing unmet medical needs, particularly in the treatment of hypogonadism. Their lead product, TSX-049, is a novel oral formulation of Testosterone Undecanoate (TU) designed to restore normal testosterone levels in males suffering from this condition. The formulation has undergone successful preclinical studies, including a confirmative study in canines, which demonstrated enhanced bioavailability and a favorable pharmacokinetic profile. TesoRx is preparing to advance TSX-049 into Phase 1-2a human clinical trials, with the goal of obtaining FDA approval by early 2026.

A significant challenge in the oral delivery of testosterone is its high first-pass metabolism, which reduces the drug's bioavailability. TesoRx's proprietary technology addresses this issue by formulating TU in a coated capsule that, upon release in the small intestine, forms neoliposomal complexes. These complexes are absorbed directly into the lymphatic system, allowing the drug to bypass the liver and enter the bloodstream more effectively. This innovative approach not only enhances the bioavailability of testosterone but has also been applied to other therapeutic areas, including chemotherapy, showcasing the versatility of TesoRx's oral delivery platform.

United States

TesoRx Pharma is a pharmaceutical company that specializes in developing a first-in-class unmodified oral testosterone for androgen deficiency.

TesoRx

Company Details